← boardnext 2027-09
KTTA
Pasithea Therapeutics Corp.distress 4/10 · elevated risk$0.48+4%today-67% from 52w high
Oncology 1
Lead: NF1 Mutation
Revenue
pre-revenue
Liquidity
$50M
Runway
3.0 yrs
Shares 1y
+349%
Price & events
-47.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.3%
1D
+5.0%
1W
-15.5%
1M
-30.3%
3M
-46.7%
6M
-33.3%
1Y
-91.7%
2Y
—
5Y
-99.3%
All
Overview
- Market Cap
- $16.04M
- Volume
- 117.26K
- 52 Week Range
- $0.29 – $1.47
- Total Shares
- 33.41M
- Float Shares
- 16.62M
- Short %
- 0.87%
- % Held by Insiders
- 1.11%
- % Held by Institutions
- 70.34%
- RVOL
- 0.10x
- Beta
- 0.29
Pipeline stages · 1 programs
PAS-004 Tablets
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-01 | Phase 1 | PAS-004 Tablets | NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1) | — | recruiting |
| 2026-02 | Phase 1 | PAS-004 Capsules, PAS-004 Tablets | RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors | 48 | recruiting |
Catalyst news & presentations · 2
- first quarter of 2026readoutPhase 1PAS-004 · Initial interim clinical data from first two cohorts of Phase 1/1b trialSEC 8-K
- 2025-11-25partnershipPAS-004 · ALS Association awarded ~$1 million Hoffman ALS Clinical Trial Award to study PAS-004 in ALS.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 33,414,448 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $3 (+525% upside) · 1 analysts
- 2026-06-16HC Wainwright & Co.Buy
- 2026-04-20HC Wainwright & Co.Buy
- 2025-12-08HC Wainwright & Co.Buy
Competitors — NF1 Mutation
- none identified
Recent news
- 2026-07-21Pasithea Therapeutics (KTTA) Registration filing Summary - Quartr
- 2026-07-21Pasithea Therapeutics (KTTA) Proxy filing Summary - Quartr
- 2026-07-21Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative
- 2026-07-21Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot - Stock Titan
- 2026-07-21Pasithea Therapeutics Announces Presentation of PAS-004 - GlobeNewswire
- 2026-07-08Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewswire
- 2026-07-08Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - Yahoo Finance
- 2026-07-02Pasithea Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Surge - Tax Rate Impact - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.